Abstract: A token adjustment system may include a carbon conversion device operable to generate a syngas from a greenhouse gas and a processing device. The processing device may be operable to receive one or more measurements. The one or more measurements may include one or more of an input flow measurement received from an input flow sensor, an output flow measurement received from an output flow sensor, or a utility measurement received from a utility sensor. The processing device may be operable to compute a carbon balance, a carbon intensity, or a carbon adjustment based on the one or more measurements. The processing device may be operable to cause a token to be generated or consumed based on the carbon balance, the carbon intensity, or the carbon adjustment.

Abstract: A method of detecting the state of a gap between an electrode and a workpiece in electrical discharge machining (EDM) equipment, the method including the steps of: prior to generating an electrical discharge to remove material from the workpiece, applying a low energy checking pulse across the gap during a checking phase period (Tc); and inferring a short circuit gap state when the gap current exceeds a current threshold (IT).

Abstract: A fiber optic cable includes a core, armor surrounding the core, and a jacket surrounding the armor. The core includes tubes, each tube having a passage defined therein, optical fibers positioned in the passages, and a binder sleeve defining an exterior of the core. Portions of the binder sleeve are directly bonded to the armor, while other portions are not. Spacing between the armor and the core, as well as the bond between the armor and binder sleeve, facilitate tubing-off of an end section of the cable to include removal of the binder sleeve.

Abstract: A method of detecting the state of a gap between an electrode and a workpiece in electrical discharge machining (EDM) equipment, the method including the steps of: prior to generating an electrical discharge to remove material from the workpiece, applying a low energy checking pulse across the gap during a checking phase period (Tc); and inferring a short circuit gap state when the gap current exceeds a current threshold (IT).

Abstract: The present invention relates to a combination of (a) a chemokine receptor 1 (CCR1) antagonist and (b) a muscarinic antagonist. The invention further relates to pharmaceutical compositions comprising said combination and to methods of treatment of airway diseases, such as chronic obstructive pulmonary disease (COPD) and asthma in mammals by administrating said combination. The invention further relates to a kit comprising the combination and use of said kit in treatment of airway diseases.

Abstract: The present invention provides a pharmaceutical product comprising, in combination of, (a) a (therapeutically effective) dose of a first active ingredient, which is a compound of formula (I) or a pharmaceutically acceptable salt thereof; and (b) a (therapeutically effective) dose of a second active ingredient, which is a glucocorticoid receptor agonist; and optionally, (c) a (therapeutically effective) dose of a third active ingredient, which is a ?2-agonist. The invention further relates to pharmaceutical compositions comprising said combination and to methods of treating treatment of airway diseases, especially chronic obstructive pulmonary disease (COPD) and asthma in mammals by administrating said combination. The invention further relates to a kit comprising the combination and use of said kit in treatment of airway diseases such as COPD and asthma.

Abstract: Compounds of formula (I) wherein R1, R3, R4, R5, R6, R7, and R10 are as defined in the specification, are described. The present invention also relates to pharmaceutical composition comprising said compounds and to the use of said compounds in therapy. The present invention further relates to processes for the preparation of said compounds and to new intermediates useful in the preparation thereof. Beside, the invention relates to salts and polymorphic forms of the new compounds as well as the preparation thereof.

Abstract: Compounds of formula (I) wherein R1, R3, R4, R5, R6, R7, and R10 are as defined in the specification, are described. The present invention also relates to pharmaceutical composition comprising said compounds and to the use of said compounds in therapy. The present invention further relates to processes for the preparation of said compounds and to new intermediates useful in the preparation thereof. Beside, the invention relates to salts and polymorphic forms of the new compounds as well as the preparation thereof.